Y.D. More Investments Ltd Lowers Position in Kamada Ltd. (NASDAQ:KMDA)

Key Points

• Y.D. More Investments Ltd has reduced its stake in Kamada Ltd. by 33.8%, selling 168,568 shares, resulting in ownership of 330,354 shares valued at approximately $2.18 million.
• Several institutional investors have altered their positions, including Huntleigh Advisors Inc. and NewEdge Advisors LLC, indicating increased interest in Kamada's stock.
• Kamada's stock has a current price of $7.01 with a market capitalization of $403.15 million, and the company recently reported earnings meeting analysts' expectations with $0.07 EPS.

Y.D. More Investments Ltd decreased its stake in shares of Kamada Ltd. (NASDAQ:KMDA - Free Report) by 33.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 330,354 shares of the biotechnology company's stock after selling 168,568 shares during the period. Y.D. More Investments Ltd owned about 0.57% of Kamada worth $2,181,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Geode Capital Management LLC grew its stake in shares of Kamada by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock worth $178,000 after buying an additional 1,549 shares in the last quarter. NewEdge Advisors LLC grew its position in shares of Kamada by 54.2% in the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock worth $143,000 after buying an additional 8,260 shares during the last quarter. JPMorgan Chase & Co. purchased a new position in shares of Kamada in the 4th quarter worth approximately $67,000. Finally, Huntleigh Advisors Inc. purchased a new stake in Kamada during the 1st quarter worth approximately $863,000. 20.38% of the stock is currently owned by institutional investors.

Kamada Stock Up 3.6%

Shares of KMDA traded up $0.25 during midday trading on Monday, reaching $7.37. 34,587 shares of the stock were exchanged, compared to its average volume of 135,874. The company has a market cap of $424.08 million, a price-to-earnings ratio of 25.43, a P/E/G ratio of 0.86 and a beta of 0.93. The firm has a 50 day simple moving average of $7.40 and a 200-day simple moving average of $7.05. Kamada Ltd. has a 12-month low of $5.17 and a 12-month high of $9.15.

Kamada (NASDAQ:KMDA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported $0.07 EPS for the quarter, hitting analysts' consensus estimates of $0.07. The company had revenue of $44.02 million for the quarter, compared to analyst estimates of $154.06 million. Kamada had a return on equity of 6.31% and a net margin of 9.60%. Research analysts expect that Kamada Ltd. will post 0.23 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Wall Street Zen upgraded shares of Kamada from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, May 21st. Benchmark restated a "buy" rating and issued a $15.00 price target on shares of Kamada in a report on Thursday, May 15th. Finally, Sidoti raised Kamada to a "hold" rating in a research report on Thursday, May 8th.

Kamada Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.